CUI Zhao,LI Shuo,WANG Hua-jing,et al.Effect of Dihydroartemisinin on Oxidative Damage and Energy Metabolism of HepG2 Cells and Its Synergistic Effect with Sorafenib[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(12):24-32.
CUI Zhao,LI Shuo,WANG Hua-jing,et al.Effect of Dihydroartemisinin on Oxidative Damage and Energy Metabolism of HepG2 Cells and Its Synergistic Effect with Sorafenib[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(12):24-32. DOI: 10.13422/j.cnki.syfjx.20211202.
Effect of Dihydroartemisinin on Oxidative Damage and Energy Metabolism of HepG2 Cells and Its Synergistic Effect with Sorafenib
To explore the inhibitory effect of dihydroartemisinin (DHA) on the proliferation of HepG2 cells, elucidate the mechanism from the perspectives of oxidative damage and energy metabolism, and discuss the possibility of combined use of DHA with sorafenib (Sora).
Method
2
Cell counting kit-8 (CCK-8) assay was used to obtain the 50% inhibitory concentration (IC
50
) of DHA and Sora on HepG2 and SW480 cells and Chou-Talalay method was used to obtain the combination index (CI) of DHA and Sora. HepG2 cells were classified into the control group, DHA group (10 µmol·L
-1
), Sora group (5 µmol·L
-1
), and DHA + Sora group (DHA 10 µmol·L
-1
, Sora 5 µmol·L
-1
) and then incubated with corresponding drugs for 8-12 h. Seahorse XF glycolytic rate assay kit and cell mito stress test kit were employed to respectively detect the glycolysis function of cells and oxidative phosphorylation function of mitochondria. DCFH-DA and lipid peroxidation MDA assay kit were separately used to analyze the intracellular levels of reactive oxygen species (ROS) and malondialdehyde (MDA). Western blot was applied to determine the intracellular levels of heme oxygenase-1 (HO-1) and glutamate-cysteine ligase catalytic subunit (GCLC).
Result
2
Compared with the control group, DHA alone inhibited the ATP synthesis in mitochondrial oxidative phosphorylation and glycolysis (
P
<
0.01), increased the levels of intracellular ROS and MDA (
P<
0.05), and decreased the levels of HO-1 and GCLC (
P<
0.05) in HepG2 cells. DHA and Sora had synergistic inhibitory effect on proliferation of HepG2 and SW480 cells, with CI
<
0.90. The DHA + Sora group showed stronger suppression of ATP synthesis in mitochondrial oxidative phosphorylation and glycolysis (
P
<
0.01), higher levels of intracellular ROS and MDA (
P<
0.01), and lower levels of intracellular antioxidation-related proteins HO-1 and GCLC in HepG2 cells (
P<
0.01) than the DHA group.
Conclusion
2
DHA may increase the level of MDA by reducing HO-1 and GCLC and increasing ROS in HepG2 cells, which results in mitochondria oxidative damage, restricts cell glycolysis and mitochondrial oxidative phosphorylation, and thus finally inhibits the proliferation of HepG2 cells. DHA and Sora have synergistic inhibitory effect on the proliferation of HepG2 and SW480 cells, and the mechanism may be related to the synergistic oxidative damage that affects the mitochondrial electron transport chain and suppresses cell energy metabolism.
关键词
Keywords
references
SUNG H , FERLAY J , SIEGEL R L , et al . Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin , 2021 , 68 ( 6 ): 394 - 424 .
PALMER D H . Sorafenib in advanced hepatocellular carcinoma [J]. N Engl J Med , 2008 , 359 ( 23 ): 2498 - 2499 .
SIEGEL A B , OLSEN S K , MAGUN A , et al . Sorafenib:where do we go from here? [J]. Hepatology , 2010 , 52 ( 1 ): 360 - 369 .
ABDEL-RAHMAN O , LAMARCA A . Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib:a systematic-review and Meta-analysis of the impact on survival [J]. Expert Rev Gastroenterol Hepatol , 2017 , 11 ( 1 ): 75 - 83 .
LU X , EFFERTH T . Repurposing of artemisinin-type drugs for the treatment of acute leukemia [J]. Semin Cancer Biol , 2020 , doi: 10.1016/j.semcancer.2020.05.016 http://dx.doi.org/10.1016/j.semcancer.2020.05.016 .
EFFERTH T . From ancient herb to modern drug:artemisia annua and artemisinin for cancer therapy [J]. Semin Cancer Biol , 2017 , 46 : 65 - 83 .
ELING N , REUTER L , HAZIN J , et al . Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells [J]. Oncoscience , 2015 , 2 ( 5 ): 517 - 532 .
LIN R , ZHANG Z , CHEN L , et al . Dihydroartemisinin (DHA) induces ferroptosis and causes cell cycle arrest in head and neck carcinoma cells [J]. Cancer Lett , 2016 , 381 ( 1 ): 165 - 175 .
XU W , WANG H , TANG T , et al . Effect of dihydroartemisinin on plasmodium NADH-dependent glutamate synthase:the implication in malaria management [J]. Am J Chin Med , 2019 , 47 ( 6 ): 1325 - 1343 .
EFFERTH T . Cancer combination therapies with artemisinin-type drugs [J]. Biochem Pharmacol , 2017 , 139 : 56 - 70 .
LI Z J , DAI H Q , HUANG X W , et al . Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma [J]. Acta Pharmacol Sin , 2021 , 42 ( 2 ): 301 - 310 .
COBBOLD S A , VAUGHAN A M , LEWIS I A , et al . Kinetic flux profiling elucidates two independent acetyl-CoA biosynthetic pathways in Plasmodium falciparum [J]. J Biol Chem , 2013 , 288 ( 51 ): 36338 - 36350 .
KE H , LEWIS I A , MORRISEY J M , et al . Genetic investigation of tricarboxylic acid metabolism during the Plasmodium falciparum life cycle [J]. Cell Rep , 2015 , 11 ( 1 ): 164 - 174 .
LI S , HUANG P , GAN J , et al . Dihydroartemisinin represses esophageal cancer glycolysis by down-regulating pyruvate kinase M2 [J]. Eur J Pharmacol , 2019 , 854 : 232 - 239 .
GAO P , SHEN S , LI X , et al . Dihydroartemisinin inhibits the proliferation of leukemia cells K562 by suppressing PKM2 and GLUT1 mediated aerobic glycolysis [J]. Drug Des Devel Ther , 2020 , 14 : 2091 - 2100 .
CHOU T C . Theoretical basis,experimental design,and computerized simulation of synergism and antagonism in drug combination studies [J]. Pharmacol Rev , 2006 , 58 ( 3 ): 621 - 681 .
GALLAMINI A , ZWARTHOED C , BORRA A . Positron emission tomography (PET) in oncology [J]. Cancers (Basel) , 2014 , 6 ( 4 ): 1821 - 1889 .
BRAS M , QUEENAN B , SUSIN S A . Programmed cell death via mitochondria:different modes of dying [J]. Biochemistry (Mosc) , 2005 , 70 ( 2 ): 231 - 239 .
PIANTADOSI C A , ZHANG J . Mitochondrial generation of reactive oxygen species after brain ischemia in the rat [J]. Stroke , 1996 , 27 ( 2 ): 327 - 331 .
AVERY S V . Molecular targets of oxidative stress [J]. Biochem J , 2011 , 434 ( 2 ): 201 - 210 .
BLAJSZCZAK C , BONINI M G . Mitochondria targeting by environmental stressors:implications for redox cellular signaling [J]. Toxicology , 2017 , 391 : 84 - 89 .
LOBODA A , DAMULEWICZ M , PYZA E , et al . Role of Nrf2/HO-1 system in development,oxidative stress response and diseases:an evolutionarily conserved mechanism [J]. Cell Mol Life Sci , 2016 , 73 ( 17 ): 3221 - 3247 .
PIANTADOSI C A , CARRAWAY M S , BABIKER A , et al . Heme oxygenase-1 regulates cardiac mitochondrial biogenesis via Nrf2-mediated transcriptional control of nuclear respiratory factor-1 [J]. Circ Res , 2008 , 103 ( 11 ): 1232 - 1240 .
LU S C . Regulation of glutathione synthesis [J]. Mol Aspects Med , 2009 , 30 ( 1/2 ): 42 - 59 .